Insider Purchases: Inside the Buy

Tag: defensive stocks

Illustration of Kimberly-Clark brands (tissues and diapers) alongside a Band-Aid and pill bottle, symbolizing KMB’s shift toward health and personal care while highlighting its high dividend yield.

Band-Aids & Bottom Lines: Why Kimberly-Clark’s 5% Yield Is the Ultimate Turnaround Play

KMB isn’t flashy—but it might be one of 2026’s sneakiest high-yield turnarounds. A $1M insider buy, heavy institutional ownership, and a big strategic pivot (hello, Tylenol & Band-Aids via Kenvue) have the market nervous… and contrarians intrigued.

Read entire article

Tags: buy or sell kmb, Consumer Staples, contrarian investment, contrarian play, Defensive Stocks, director buying, Dividend aristocrat, Dividend Stocks, featured-insiders, funanc1al edge, funanc1al investing, Healthcare & Personal Care, hub-insiders, Income Investing, Insider Buying, kenvue, Kimberly-Clark, KMB, merger, Risks buying KMB, share buyback, Todd Maclin, turnaround play, Turnaround Stories, Value Investing, why buy KMB
Illustration of Abbott Laboratories stock analysis showing CEO insider buying, medical devices, and healthcare growth themes for ABT shares.

CEO Purchases Abbott Shares, But the Stock Carries Risks

Abbott’s CEO just stepped in with a $2M insider buy — analysts are bullish, shorts are scarce, and institutions remain locked in. Tempting? Yes. Risk-free? Not quite.

Read entire article

Tags: 2026 Stock Ideas, Abbott Laboratories, ABT, buy or sell ABT, CEO Conviction, CEO insider buying, CEO Insider Purchases, CEO Stock Purchase, CEOBuyIn, CEOConfidence, COB insider buy, Defensive Stocks, Dividend Stocks, featured-insiders, FUNanc1al Edge, FUNanc1al Humor, FUNanc1al Investing, FunStock Index, Healthcare Stocks, hub-insiders, Insider Buying, Large Cap Stocks, Medical Devices, risks buying ABT, why buy ABT
Coca-Cola (KO) director insider buy with dividend coin stack—global beverage portfolio, steady cash flow, and defensive growth.

A Director Bought Shares of Coca-Cola (KO) Hoping They’ll Sparkle; Should You—Or Will They Fizzle Out?

A fresh insider buy from new director Max Levchin adds fizz to Coca-Cola’s already solid fundamentals: mid-single-digit organic growth, fortress cash flow, and a Dividend King pedigree. We break down the bull/bear case, valuation, and why KO still shines—especially on dips.

Read entire article

Tags: Berkshire Hathaway, beverage industry, Buy KO Stock, cash flow, Coca-Cola, consumer staples, defensive stocks, DIrector Buying, Director Insider Buying, dividend stocks, Earnings, insider buying, KO Stock, Max Levchin, portfolio income, valuation, Warren Buffett